Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study

[Introduction] Angiosarcomas constitute approximately 2% to 3% of all soft tissue sarcomas, are characterised by an aggressive clinical behaviour and poor outcome. Optimal management of localised angiosarcomas consists of complete surgical resection with or without radiation. However, due to the inf...

Descripción completa

Detalles Bibliográficos
Autores: Constantinidou, Anastasia, Sauve, Nicolas, Stacchiotti, Silvia, Blay, Jean-Yves, Vincenzi, Bruno, Grignani, Giovanni, Rutkowski, Piotr, Guida, Michele, Hindi, Nadia, Klein, Alexander, Thibaud, Valentin, Sufliarsky, Jozef, Desar, Ingrid, Steeghs, Neeltje, Litiere, Saskia, Gelderblom, Hans, Jones, Robin L.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/234191
Acceso en línea:http://hdl.handle.net/10261/234191
Access Level:acceso abierto
Palabra clave:Angiosarcoma
Neoadjuvant
Adjuvant
Sarcoma chemotherapy
Angiosarcoma surgery
Descripción
Sumario:[Introduction] Angiosarcomas constitute approximately 2% to 3% of all soft tissue sarcomas, are characterised by an aggressive clinical behaviour and poor outcome. Optimal management of localised angiosarcomas consists of complete surgical resection with or without radiation. However, due to the infiltrating nature of this disease, complete resection is often not possible. Despite optimal management, the outcome of patients with localised disease remains poor. The role of (neo)adjuvant chemotherapy in angiosarcomas remains undefined. The aim of this study is to document the outcome of patients treated with (neo)adjuvant chemotherapy and assess the feasibility of performing a prospective trial by evaluating the number of patients treated at sarcoma referral centres.